EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cadila Healthcare Limited (532321) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Cadila Healthcare Limited ₹753, price ₹1,145, upside -34.3%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · IN · ISIN INE010B01027

CH Thin data Sep 24, 2026

Cadila Healthcare Limited

532321 · BSE

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value ₹752.60 · Overvalued (−34.3%)
✓Quality 61/100
!Mixed Growth (revenue 5y +8.6 %/yr)
✓Solidly profitable · 11.4% net margin (TTM)
✓Low debt
✓0.6% dividend yield · Well covered
!Moderate moat 58/100
!Evidence only low, so the estimate is less certain
Watch Cadila Healthcare Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,286 ₹319.57 Fair Value ₹752.60 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹319.57 – ₹1,286 · fair‑value band ₹491.40 – ₹1,148 · the ₹1,145 price screens above the ₹752.60 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally.

Show more

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company offers products in the therapeutic areas of pain management, neurology, dermatology, rare diseases, specialty oncology, gastroenterology, and liver diseases. It also provides consumer wellness products, such as Sugar Free and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.

Stock analysis

Cadila Healthcare Limited (532321) currently trades at ₹1,145, while our model-based Fair Value estimate is ₹752.60, 34.3% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ₹417.93 per share, and 0 of the 26 models we run sit above the ₹1,145 price.

Bear case: the Asset-Based group reads lowest at ₹85.03, and 26 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹491.40 (bear) to ₹1,148 (bull), the price of ₹1,145 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cadila Healthcare Limited reported revenue of ₹145B in FY2021 versus ₹95.7B in FY2017, a compound +10.9%/yr. Reported net income was ₹21.3B in FY2021, compounding +9.4%/yr from FY2017.

Key figures

Market cap ₹438B (≈ $4.5B) · P/E ratio 25.8 · P/S ratio 3.79 · EPS (TTM) ₹16.55 · Dividend yield 0.6% · Net margin 14.7% · Return on equity 13.5% · Return on assets (EBIT) 10.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −34%, 532321 screens richer than that median.

Fair Value models

Bear ₹491.40 Fair Value ₹752.60 Bull ₹1,148
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ₹258.77 ₹417.93 ₹663.89 78
Growth DCF ₹259.93 ₹412.49 ₹643.73 77
Owner Earnings ₹222.58 ₹359.44 ₹570.92 75
All 26 models by family
DCF Models
FCF DCF ₹258.77 ₹417.93 ₹663.89 78
Owner Earnings ₹222.58 ₹359.44 ₹570.92 75
5Y Revenue Exit ₹217.07 ₹349.29 ₹520.59 71
5Y EBITDA Exit ₹270.24 ₹452.71 ₹671.12 74
5Y P/E Exit ₹292.15 ₹495.32 ₹715.98 70
10Y Revenue Exit ₹223.58 ₹348.66 ₹523.18 66
10Y EBITDA Exit ₹263.38 ₹420.36 ₹639.66 67
10Y P/E Exit ₹277.25 ₹449.90 ₹674.38 63
Earnings-Based
Graham-Dodd ₹141.72 ₹526.98 ₹712.24 64
Lynch FV ₹126.63 ₹180.90 ₹235.17 61
PEG = 1.0 ₹126.63 ₹180.90 ₹235.17 57
EPV ₹173.08 ₹200.33 ₹223.83 74
Dividend Discount
Gordon GGM ₹0.1300 ₹0.2600 ₹0.3900 67
DDM Multi-Stage ₹0.1300 ₹0.2200 ₹0.2700 67
Multiples
P/E Multiple ₹343.88 ₹458.51 ₹573.13 63
P/S Multiple ₹265.73 ₹354.30 ₹442.88 58
P/B Multiple ₹265.73 ₹354.30 ₹442.88 55
EV/EBIT ₹282.36 ₹376.30 ₹470.24 66
EV/EBITDA ₹306.97 ₹409.11 ₹511.25 67
EV/Revenue ₹201.68 ₹287.89 ₹374.09 53
Asset-Based
NCAV (Graham) ₹63.46 ₹85.03 ₹126.91 54
Growth DCF
Growth DCF ₹259.93 ₹412.49 ₹643.73 77
Rev-Margin DCF ₹217.07 ₹349.07 ₹508.80 72
Economic Profit
Residual Income ₹131.87 ₹171.68 ₹271.95 74
ROIC Compounder ₹185.93 ₹240.64 ₹310.40 72
Growth Earnings
Growth-Adj P/E ₹241.84 ₹345.49 ₹449.14 67

Open the full fair value analysis →

Notify me when 532321 reaches fair value

Put 532321 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 61/100

Of which business quality 61 · Market factors (momentum, volatility) 69

Profitability 60
Margins and returns on capital today
Quality Growth 66
Are margins and returns improving?
Cashflow 69
Earnings quality: real cash, not paper profit
Fin. Strength 54
Balance sheet, leverage, solvency risk
Investment 53
Disciplined investing over empire-building
Low Volatility 89
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 63
Distance to the 52-week high (market factor)

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.2% (2016) → 15.6% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

532321 screens overvalued: fair value 34% below the price. Compare with Merck KGaA →

Compare Cadila Healthcare Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside −72.3% · Bottom 25%
Profitability
Return on equity (TTM) 13.5% · Top 25%
Return on assets 6.5% · Top 25%
Net margin (TTM) 11.4% · Above median
Operating margin (TTM) 16.7% · Above median
Growth and dividend
Revenue growth 13.5% · Above median
Dividend yield (TTM) 0.6% · Below median
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 25.8× · Pricier than median
P/B 3.37× · Priciest 25%
P/S (TTM) 2.95× · Pricier than median
EV/EBITDA 13.9× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cadila Healthcare Limited · Fair Value
₹752.60 −34%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cadila Healthcare Limited Fair Value". https://www.fairvalue-calculator.com/stock/532321

Frequently asked questions

Is Cadila Healthcare Limited (532321) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹752.60 versus a price of ₹1,145, about −34% upside (overvalued).
What is the fair value of 532321?
Our model-based fair value for Cadila Healthcare Limited is ₹752.60 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹1,145.
What is the quality score of 532321?
Cadila Healthcare Limited has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cadila Healthcare Limited (532321)?
Our model-based price target is the fair value of ₹752.60 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹491.40, optimistic scenario ₹1,148. It is a calculation from audited fundamentals, not an analyst target.
What is the Cadila Healthcare Limited stock forecast for 2026?
Our models put fair value at ₹752.60, about −34% upside versus a price of ₹1,145 (overvalued). Cautious scenario ₹491.40, optimistic scenario ₹1,148. The calculation is refreshed regularly with new filings.
What is the revenue of Cadila Healthcare Limited (532321)?
Cadila Healthcare Limited reported trailing-twelve-month revenue of about ₹149B (latest available figure, as of Sep 24, 2026).
Does Cadila Healthcare Limited pay a dividend?
Cadila Healthcare Limited currently shows a dividend yield of about 0.61% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Cadila Healthcare Limited (532321)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cadila Healthcare Limited it is ₹752.60 per share (as of Sep 24, 2026), against a price of ₹1,145. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Cadila Healthcare Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 532321 trades above its calculated fair value: price ₹1,145, fair value ₹752.60, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 532321?
No. The price is what the market pays today (₹1,145); the fair value is what the company's own numbers justify (₹752.60). For Cadila Healthcare Limited the two are ₹392.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cadila Healthcare Limited worth?
The market values Cadila Healthcare Limited at about ₹438B (market capitalisation, as of Sep 24, 2026). Per share that is ₹1,145; our models calculate a fair value of ₹752.60 per share.
What do the bullish and bearish scenarios say about 532321?
Our models span a range for Cadila Healthcare Limited: cautious scenario ₹491.40, base ₹752.60, optimistic ₹1,148 per share (as of Sep 24, 2026, price ₹1,145). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 532321?
Cadila Healthcare Limited trades at a price-to-earnings ratio of 25.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹752.60 is built from several models across several years. Other multiples: P/B 3.4, P/S 3.0, EV/EBITDA 13.9.
How solid is the balance sheet of Cadila Healthcare Limited (532321)?
Balance-sheet figures for Cadila Healthcare Limited (as of Sep 24, 2026): return on equity 13.5%, debt of 0.05 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 532321 from its 52-week high?
Cadila Healthcare Limited trades at ₹1,145, about 6% below its 52-week high of ₹1,212 and 33% above the low of ₹859.78 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹752.60 is for.
Which stocks are comparable to Cadila Healthcare Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cadila Healthcare Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹1,145, calculated fair value ₹752.60 (−34%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 532321 calculated?
We run Cadila Healthcare Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹752.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cadila Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cadila Healthcare Limited (532321)?
The closing price on Oct 1, 2026 was ₹1,145. Our model-based fair value is ₹752.60, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cadila Healthcare Limited right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹491.40 to ₹1,148) leaves room in how you read the outcome.

Key figures of Cadila Healthcare Limited

How large is the market capitalisation of Cadila Healthcare Limited (532321)?
The market capitalisation of Cadila Healthcare Limited is ₹438B (≈ $4.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cadila Healthcare Limited (532321)?
The price-to-sales ratio of Cadila Healthcare Limited is 3.79 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cadila Healthcare Limited (532321)?
Earnings per share at Cadila Healthcare Limited are ₹16.55 (price ÷ EPS = P/E 25.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cadila Healthcare Limited (532321)?
The dividend yield of Cadila Healthcare Limited is 0.6% (payout 42.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cadila Healthcare Limited (532321)?
The net margin of Cadila Healthcare Limited is 14.7% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cadila Healthcare Limited (532321)?
The return on equity (ROE) of Cadila Healthcare Limited is 13.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cadila Healthcare Limited (532321)?
On an EBIT basis the return on assets of Cadila Healthcare Limited is 10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cadila Healthcare Limited (532321)?
The operating margin of Cadila Healthcare Limited is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cadila Healthcare Limited (532321)?
Revenue at Cadila Healthcare Limited is growing +13.5% versus a year earlier (3y avg +6.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cadila Healthcare Limited (532321)?
Earnings per share at Cadila Healthcare Limited are growing +340% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Cadila Healthcare Limited in the live analysis

One click puts Cadila Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.